Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Oncologist On-Call: Thoughts on the Current Treatment Landscape for First-line Management of HER2-Positive mBC

14:42
 
Share
 

Manage episode 473319706 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including:

  • Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastuzumab deruxtecan (T-DXd) in patients with advanced HER2-positive metastatic breast cancer and 2 or fewer previous therapies
  • Treatment sequencing and preferred treatment options in patients with brain metastases
  • Results from phase III PATINA trial of trastuzumab, pertuzumab, plus endocrine therapy with or without palbociclib in hormone-receptor positive/HER2-positive metastatic breast cancer
  • Thoughts on the use of T-DXd earlier in the treatment paradigm in light of recent results from the PATINA trial and highly anticipated results from the DESTINY-Breast09 trial

Program faculty:

Stephanie L. Graff, MD, FACP, FASCO
Director of Breast Oncology, Brown University Health
Co-Lead, Breast Cancer Translational Disease Research Group
Legorreta Cancer Center at Brown University
Associate Professor of Medicine
Warren Alpert Medical School of Brown University
Providence, Rhode Island

Laura M. Spring, MD
Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Resources:
To access the patient cases associated with this podcast discussion, please visit the program page and register for an upcoming webinar on this topic.

  continue reading

191 episodes

Artwork
iconShare
 
Manage episode 473319706 series 3256997
Content provided by Clinical Care Options, LLC and Clinical Care Options. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clinical Care Options, LLC and Clinical Care Options or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including:

  • Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastuzumab deruxtecan (T-DXd) in patients with advanced HER2-positive metastatic breast cancer and 2 or fewer previous therapies
  • Treatment sequencing and preferred treatment options in patients with brain metastases
  • Results from phase III PATINA trial of trastuzumab, pertuzumab, plus endocrine therapy with or without palbociclib in hormone-receptor positive/HER2-positive metastatic breast cancer
  • Thoughts on the use of T-DXd earlier in the treatment paradigm in light of recent results from the PATINA trial and highly anticipated results from the DESTINY-Breast09 trial

Program faculty:

Stephanie L. Graff, MD, FACP, FASCO
Director of Breast Oncology, Brown University Health
Co-Lead, Breast Cancer Translational Disease Research Group
Legorreta Cancer Center at Brown University
Associate Professor of Medicine
Warren Alpert Medical School of Brown University
Providence, Rhode Island

Laura M. Spring, MD
Breast Medical Oncologist
Mass General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Resources:
To access the patient cases associated with this podcast discussion, please visit the program page and register for an upcoming webinar on this topic.

  continue reading

191 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Listen to this show while you explore
Play